Parkway Neuroscience v. Katz, Abosch, etc., PA

CourtCourt of Special Appeals of Maryland
DecidedSeptember 30, 2022
Docket0658/21
StatusPublished

This text of Parkway Neuroscience v. Katz, Abosch, etc., PA (Parkway Neuroscience v. Katz, Abosch, etc., PA) is published on Counsel Stack Legal Research, covering Court of Special Appeals of Maryland primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Parkway Neuroscience v. Katz, Abosch, etc., PA, (Md. Ct. App. 2022).

Opinion

Parkway Neuroscience and Spine Institute, LLC v. Katz, Absoch, Windesheim, Gershman & Freedman, P.A., et al., No. 658, September Term, 2021, Opinion by Adkins, J.

EVIDENCE-EXPERT TESTIMONY: The admissibility of expert testimony is largely within the discretion of the trial court. Such a ruling, however, may be reversed on appeal if it is founded upon an error of law. Judges making discretionary rulings must apply correct legal standards. EVIDENCE—DAUBERT-ROCHKIND: A trial court, in its gatekeeper role under Rochkind and Daubert, acts improperly in excluding the testimony of a qualified certified public accountant testifying about lost profits of an LLC medical practice―on grounds that the expert’s experience with such analysis, although extensive, had only included one medical practice. Any lack of specialized experience is ripe for cross-examination at trial. EVIDENCE—DAUBERT-ROCHKIND: Trial court erred in holding expert testimony unreliable under the Daubert-Rochkind standard after accepting expert’s methodology— the before-and-after method of calculating lost profits. Court’s rationale was (1) using 2015 as the base year; (2) failing to consider changes in insurance reimbursement rates; (3) failing to articulate standards to define economic impact and treat member draws; (4) changing her calculations while the underlying facts remained the same; and (5) failing to offer calculations for profit loss based on variable jury determinations. None of these criticisms addressed methodology, and they were more appropriate for cross-examination and advocacy at trial. EVIDENCE—MARYLAND RULE 5-702: Maryland Rule 5-702 requirement that there is “a sufficient factual basis” supporting the testimony does not justify a trial court’s exclusion of such testimony based upon the correctness of the expert’s conclusions. “[A]nalytical focus should be on principles and methodology. Trial courts may not reject expert testimony simply because they disagree with the conclusions reached by the witness.” Jack B. Weinstein, Weinstein’s Federal Evidence 702.05[2][a] (2d ed. 1997). Circuit Court for Howard County Case No. C-13-CV-18-000181

REPORTED

IN THE COURT OF SPECIAL APPEALS

OF MARYLAND

No. 0658

September Term, 2021

______________________________________

PARKWAY NEUROSCIENCE AND SPINE INSTITUTE, LLC

v.

KATZ, ABOSCH, WINDESHEIM, GERSHMAN & FREEDMAN, P.A., ET AL.

Berger, Friedman, Adkins, Sally D. (Senior Judge, Specially Assigned),

JJ. ______________________________________

Opinion by Adkins, J. ______________________________________ ______________________________________

Filed: September 30, 2022 In 1978, the Maryland Court of Appeals adopted the Frye standard for expert

testimony, which allowed admission of an expert’s testimony if the basis of that opinion

“ha[d] gained general acceptance in the particular field in which it belongs.” Reed v. State,

283 Md. 374, 381 (1978) (quoting Frye v. U.S., 293 F. 1013, 1014 (D.C. Cir. 1923)). Thus,

Maryland’s Frye-Reed standard was born. During its tenure as the evidentiary standard for

expert testimony admission in Maryland, the Supreme Court adopted a new standard for

admission of scientific expert testimony in federal courts, commonly referred to as the

Daubert1 standard. Rather than focusing on the general acceptance of the expert’s

methodology—like in Frye—the Daubert standard focuses on the reliability of the

methodology. See Daubert v. Merrell Dow Pharms., Inc., 509 U.S. 579, 589–90 (1993).

The Supreme Court later expanded the reach of Daubert by applying the standard

to admission of expert testimony that was non-scientific in nature. Kumho Tire Co., Ltd.

v. Carmichael, 526 U.S. 137, 141 (1999). The supermajority of states had already jumped

aboard the Daubert train when Maryland followed suit. In 2020, our Court of Appeals

overruled Reed v. State and adopted Daubert as the new standard for admission of expert

testimony in Maryland. Rochkind v. Stevenson, 471 Md. 1, 5 (2020). Although Maryland

courts had used a “Frye-Reed Plus” standard2—which considered some of the Daubert

factors—applying the new Daubert-Rochkind standard and sifting through the thousands

1 Daubert v. Merrell Dow Pharms., Inc., 509 U.S. 579 (1993). 2 “In the forty years that followed Reed, Maryland experienced a jurisprudential drift: the Frye-Reed standard announced in 1978 slowly morphed into a “Frye-Reed Plus” standard, implicitly and explicitly relying on and adopting several Daubert principles.” Rochkind v. Stevenson, 471 Md. 1, 5 (2020). of cases applying the Daubert standard may pose a challenge to circuit courts—as it did in

the case at hand.

Parkway Neuroscience and Spine Institute, LLC (“PNSI” or “Appellant”) brought

suit against Katz, Abosch, Windesheim, Gershman & Freedman, P.A. (“Katz Abosch”)

and Mark Rapson (collectively, “Appellees”)—its previous accounting firm and main

accountant. As a remedy, PNSI is seeking lost profits damages. In order to establish lost

profits damages, PNSI proffered the expert testimony of Meghan Cardell, a Certified

Public Accountant (“CPA”). Appellees moved to exclude Ms. Cardell’s testimony—

asserting that the methodology she employed was unreliable—and to strike the lost profits

claim. After a Daubert hearing, the Circuit Court for Howard County agreed with

Appellees and granted their motion to exclude Ms. Cardell’s testimony and strike the lost

profits claim. The circuit court—over PNSI’s opposition—granted the Appellees’ motion

for summary judgment on all remaining counts. PNSI timely appealed.

PNSI presents us with the following questions:

1. Did the Trial Court Abuse its Discretion in Granting Defendants’ Renewed Motion to Strike Plaintiff’s Lost Profits Claim and Exclude Plaintiff’s Experts Based on New Daubert Standard and Barring Meghan Cardell from Presenting Expert Testimony Regarding PNSI’s Lost Profits?

2. Did the Trial Court Erroneously Conclude that Ms. Cardell was not Qualified to Render an Expert Opinion Regarding the Lost Profits of a Medical Practice?

3. Did the Trial Court Erroneously Conclude that Ms. Cardell’s Testimony Would Not Assist the Trier of Fact?

For the following reasons, we reverse.

2 FACTS AND PROCEDURAL HISTORY

PNSI is a mixed-specialty medical practice whose practitioners provide treatment

for brain, spine, and peripheral nervous system disorders. Starting in 2011, PNSI began to

expand its operation with the hiring of more physicians and support staff. Between 2013

and 2014, PNSI had ten physician members who owned the practice. Since none of the

members had the necessary background in finance and accounting, PNSI entered into a

written agreement in October 2013 with Katz Abosch to provide tax, accounting, “and

financial guidance and direction to help PNSI continue to grow its practice.”

Appellee, Mark Rapson, is a CPA and Chair of Katz Abosch’s Medical Services

Group. Mr. Rapson—assisted by the CEO of Katz Abosch and another senior

accountant—was in charge of PNSI’s account. PNSI normally reconciled its books at the

end of the year, so Appellees allegedly agreed to prepare the reconciliation beginning at

the end of 2013. According to Appellant, Katz Abosch recommended that PNSI wait to

make its end-of-year reconciliation payments until October 2014.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Riegel v. Medtronic, Inc.
451 F.3d 104 (Second Circuit, 2006)
Daubert v. Merrell Dow Pharmaceuticals, Inc.
509 U.S. 579 (Supreme Court, 1993)
General Electric Co. v. Joiner
522 U.S. 136 (Supreme Court, 1997)
Kumho Tire Co. v. Carmichael
526 U.S. 137 (Supreme Court, 1999)
Cummings v. Standard Register Co.
265 F.3d 56 (First Circuit, 2001)
Mark A. Smith v. Ford Motor Company
215 F.3d 713 (Seventh Circuit, 2000)
Janopoulos v. Harvey L. Walner & Associates, Ltd.
866 F. Supp. 1086 (N.D. Illinois, 1994)
Gannon v. United States
571 F. Supp. 2d 615 (E.D. Pennsylvania, 2007)
Hughes v. Carter
204 A.2d 566 (Court of Appeals of Maryland, 1964)
Smolow v. Hafer
513 F. Supp. 2d 418 (E.D. Pennsylvania, 2007)
Reed v. State
391 A.2d 364 (Court of Appeals of Maryland, 1978)
Jacobs v. Flynn
749 A.2d 174 (Court of Special Appeals of Maryland, 2000)
Marksman Partners, L.P. v. Chantal Pharmaceutical Corp.
927 F. Supp. 1297 (C.D. California, 1996)
Chapin v. a & L PARTS, INC.
732 N.W.2d 578 (Michigan Court of Appeals, 2007)
Giant Food, Inc. v. Booker
831 A.2d 481 (Court of Special Appeals of Maryland, 2003)
Blackwell v. Wyeth
971 A.2d 235 (Court of Appeals of Maryland, 2009)
Astra Aktiebolag v. Andrx Pharmaceuticals, Inc.
222 F. Supp. 2d 423 (S.D. New York, 2002)
Ameristar Jet Charter, Inc. v. Dodson International Parts, Inc.
155 S.W.3d 50 (Supreme Court of Missouri, 2005)

Cite This Page — Counsel Stack

Bluebook (online)
Parkway Neuroscience v. Katz, Abosch, etc., PA, Counsel Stack Legal Research, https://law.counselstack.com/opinion/parkway-neuroscience-v-katz-abosch-etc-pa-mdctspecapp-2022.